Acumen Pharmaceuticals, Inc.

03/12/2026

The field of Alzheimer’s research is advancing rapidly toward identifying risk earlier and intervening sooner. Acumen’s Chief Medical Officer, Eric Siemers MD, is an author on a newly published paper summarizing the spring 2025 Alzheimer's Association's Research Roundtable discussion, which explored emerging biomarker advances, prevention strategies, and treatment approaches before cognitive symptoms appear.

The meeting report is now available in 'Alzheimer’s & Dementia: Translational Research & Clinical Interventions'.

Read more:

Advances in biomarker technology, digital cognitive assessments, and amyloid-targeting therapies have redefined the opportunities for accurate and early diagnosis and care of Alzheimer's disease (AD...

03/11/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

March's 'Ask Acumen' featured team member is Yuli Wu, MD, VP, Drug Safety & Pharmacovigilance.

🔗Click the link to get a behind-the-scenes look at Yuli's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

03/03/2026

We’re excited to be attending this year’s AD/PD - Advances in Science & Therapy Conference in Copenhagen. We’re presenting one oral and two poster sessions that highlight our work on enhanced brain delivery (EBD™) and antibody selectivity, advancing how we target toxic Aβ oligomers in Alzheimer’s disease. If you’re attending the conference, check out our presentations.

🔗More details are in the press release: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-showcase-advances-alzheimers-treatment

02/24/2026

Having strong company values is vital to building a positive work culture and driving Acumen's mission forward. We want to share our values with the world in the hope that they may inspire others to join us in making a meaningful impact.

Integrity is a cornerstone of our company culture at Acumen. We believe that by conducting ourselves with honesty and transparency, we can build trust and make a lasting impact in the world. Our commitment to integrity means that we hold ourselves accountable to the highest ethical standards, we strive to create a culture of integrity that extends beyond our organization and inspires others to do the same.

02/20/2026

On National Caregivers Day, we recognize and thank caregivers everywhere for the time, patience, and heart you give to others. We see you, and we’re grateful.

02/17/2026

Having strong company values is vital to building a positive work culture and driving Acumen's mission forward. We want to share our values with the world in the hope that they may inspire others to join us in making a meaningful impact.

At Acumen, we value innovation as a driving force in making a meaningful impact. We believe that by constantly pushing the boundaries of what is possible, we can advance solutions that may improve the lives of those affected by Alzheimer's Disease.

02/11/2026

Today, on International Day of Women and Girls in Science, we celebrate the women and girls whose ideas, leadership, and resilience continue to push science forward.

At Acumen, we’re honored to work alongside women across our organization and extended scientific community who are advancing innovation and helping shape the future of Alzheimer’s research. Their impact reaches far beyond today and we’re proud to support it.

02/09/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

February's 'Ask Acumen' featured team member is Kathy Marcozzi Pierce, Director, Clinical Operations.

🔗Click the link below to get a behind-the-scenes look at Kathy's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

02/04/2026

Today at the Alzheimer’s & Parkinson’s Drug Development Summit, Acumen CMO Eric Siemers MD presented on advancing disease‑modifying therapies through biomarker‑driven antibody innovation.

His session highlighted sabirnetug (ACU193), Acumen’s investigational next‑generation anti‑amyloid‑β oligomer antibody, designed to selectively target toxic Aβ oligomers. He also shared translational biomarker findings from the INTERCEPT‑AD Phase 1 trial and discussed how the ongoing ALTITUDE‑AD Phase 2 study is designed to confirm mechanistic action and evaluate clinical efficacy in early Alzheimer’s disease, with the goal of delivering meaningful outcomes for patients.

02/04/2026

We were proud to see Acumen represented on the keynote stage at the WCBP in Washington D.C. last week.

Our Senior Director of CMC Regulatory, Kathy Lee, joined industry leaders from Amgen and Danforth Health for a Keynote session on “The Heart of Innovation: Patients Shaping the Future of Biologics”.

The session highlighted how patient perspectives inform innovation across the biopharmaceutical lifecycle and why patient-centered approaches are essential to advancing access, quality, and impact.


CASSS - Sharing Science Solutions

01/26/2026

Having strong company values is vital to building a positive work culture and driving Acumen's mission forward. We want to share our values with the world in the hope that they may inspire others to join us in making a meaningful impact.

At Acumen, our top priority is people. We believe that people are the heart and soul of our company, and we are committed to making a difference in the lives of those impacted by Alzheimer's disease.

By putting people first, we ensure that our research and development efforts are geared towards creating targeted treatments that improve the quality of life for patients as well as their families and caregivers.

01/20/2026

We’re pleased to share a new Clinical Leader feature highlighting how Acumen is using a “study within a study” approach to better understand what works in Alzheimer’s trial recruitment.

Our CMO, Eric Siemers MD, and Associate Director of Communications Robyn Moxon sat down with Abby Proch to discuss how taking a closer look at our own strategies can help improve efficiency, reduce burden, and inform future trial design across the field.

Read the full conversation here: https://www.clinicalleader.com/doc/study-within-a-study-reveals-best-recruitment-strategies-for-alzheimer-s-trials-0001

In this Q&A, Acumen Pharmaceuticals shares findings from its Alzheimers recruitment study, highlighting what efforts proved the most fruitful.